Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.
News|Articles|April 9, 2026
ASCO Thyroid Cancer Guideline Updates Synthesize Evidence-Based Systemic Therapy Recommendations
Author(s)Ashling Wahner
Fact checked by: Riley Kandel, Kirsty Mackay
ASCO has published updates to the clinical practice guidelines for the use of systemic therapy across subsets of patients with thyroid cancer.
Advertisement
Advertisement
On April 1, 2026, the American Society of Clinical Oncology (ASCO) published new clinical practice guidelines with evidence-based recommendations for the use of systemic therapy across thyroid cancer subtypes.1 Read on for a snapshot of the most pertinent updates.
Related to this article
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
The FDA has approved amivantamab and hyaluronidase-lpuj for metastatic head and neck squamous cell carcinoma.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
Community hematologists/oncologists discussed bispecific antibody integration in community practice for relapsed/refractory multiple myeloma.
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
Advertisement
Advertisement